ChemoCentryx Stock Forecast, Price & News

+0.37 (+2.89 %)
(As of 06/16/2021 03:34 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume59,021 shs
Average Volume1.91 million shs
Market Capitalization$919.31 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

ChemoCentryx logo

About ChemoCentryx

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.


ChemoCentryx (NASDAQ:CCXI) Shares Gap Up to $12.18
ChemoCentryx (NASDAQ:CCXI) Shares Gap Up to $12.18
June 14, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.88 out of 5 stars

Medical Sector

139th out of 2,100 stocks

Pharmaceutical Preparations Industry

63rd out of 832 stocks

Analyst Opinion: 4.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

Is ChemoCentryx a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ChemoCentryx stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCXI, but not buy additional shares or sell existing shares.
View analyst ratings for ChemoCentryx
or view top-rated stocks.

What stocks does MarketBeat like better than ChemoCentryx?

Wall Street analysts have given ChemoCentryx a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 3,140,000 shares, an increase of 35.9% from the May 13th total of 2,310,000 shares. Based on an average daily volume of 2,650,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 5.9% of the shares of the company are short sold.
View ChemoCentryx's Short Interest

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for ChemoCentryx

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) posted its earnings results on Thursday, April, 29th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.03. The biopharmaceutical company earned $10.35 million during the quarter, compared to analyst estimates of $8.69 million. ChemoCentryx had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 91.54%.
View ChemoCentryx's earnings history

How has ChemoCentryx's stock been impacted by Coronavirus (COVID-19)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CCXI stock has decreased by 68.3% and is now trading at $13.18.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CCXI?

9 analysts have issued 12-month target prices for ChemoCentryx's stock. Their forecasts range from $17.00 to $70.00. On average, they expect ChemoCentryx's stock price to reach $38.00 in the next year. This suggests a possible upside of 188.3% from the stock's current price.
View analysts' price targets for ChemoCentryx
or view top-rated stocks among Wall Street analysts.

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 62, Pay $1.13M)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer, Sec. and Director (Age 58, Pay $757.77k)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 60, Pay $607.52k)
  • Mr. Tausif Butt, Exec. VP & COO (Age 55)
  • Ms. Kari E. Leetch, Sr. VP of HR
  • Ms. Dalia R. Rayes, Sr. VP & Head of Commercial
  • Dr. Sangita Ghosh Ph.D., Sr. VP of Technical Operations

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.13%), RA Capital Management L.P. (5.10%), TimesSquare Capital Management LLC (2.22%), Wasatch Advisors Inc. (1.56%), Geode Capital Management LLC (1.22%) and Cormorant Asset Management LP (1.22%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., D. E. Shaw & Co. Inc., Cormorant Asset Management LP, Emerald Advisers LLC, Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, Octagon Capital Advisors LP, and UBS Group AG. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx
or view top insider-selling stocks.

Which major investors are buying ChemoCentryx stock?

CCXI stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Morgan Stanley, Nuveen Asset Management LLC, BlackRock Inc., Polar Capital Holdings Plc, Citigroup Inc., Barclays PLC, and Lord Abbett & CO. LLC.
View insider buying and selling activity for ChemoCentryx
or or view top insider-buying stocks.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $13.18.

How much money does ChemoCentryx make?

ChemoCentryx has a market capitalization of $919.31 million and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55,360,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 133 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is

Where are ChemoCentryx's headquarters?

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.